| 产品描述： | Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity |
| 靶点： |
IL-2;IL-5;IL-13;ILReceptor; Interleukin |
| 体内研究： |
Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma. Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum |
| 参考文献： |
1. Yanagihara Y, et, al. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response. Jpn J Pharmacol. 1993 Jan;61(1):31-9. 2. Zhao GD, et, al. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol. 2000 Feb;121(2):116-22. 3. Kurokawa M, et, al. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 2001 Dec;10(6):333-7. 4. Furonaka M, Hattori N, Tanimoto T, Senoo T, Ishikawa N, Fujitaka K, Haruta Y, Yokoyama A, Kohno N. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther. 2009 Jan;328(1):55-61. |
| 溶解性： |
Soluble in DMSO、H2O |
| 保存条件： |
RT |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.001 ml |
10.007 ml |
20.014 ml |
| 5 mM |
0.4 ml |
2.001 ml |
4.003 ml |
| 10 mM |
0.2 ml |
1.001 ml |
2.001 ml |
| 50 mM |
0.04 ml |
0.2 ml |
0.4 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京